News & insights

Rare & Inherited Disease Genomics

Rare and inherited diseases affect millions of patients worldwide, many of whom wait years for a diagnosis. Germline genomic testing, from targeted panels to exomes and genomes, has become central to shortening that diagnostic journey, provided labs can efficiently prioritize the variants that explain each patient's phenotype.

In this section, you will find our articles on rare and inherited disease genomics: germline variant interpretation, phenotype-driven prioritization, CNV detection, case studies from diagnostic labs, and updates on how SeqOne helps teams reach more diagnoses, faster.

Delivering Personalized Oncology for Patients: Integrating Molecular Signatures in Clinical Practice

Rewatch our webinar to discover how molecular signatures like HRD and IGHV mutational status are used in clinical practice to deliver personalized oncology.

SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine

Strategic acquisition of UK genomics leader Congenica reinforces SeqOne market position and footprint - servicing over 160 labs in 30+ countries.

AI in Clinical Genomics: The Science and Real-World Impact of AI on Variant Interpretation

Rewatch our webinar to discover how AI is revolutionizing clinical genomics, speeding up variant interpretation, and enhancing diagnostic accuracy.

SeqOne Appoints Bioinformatics Veteran Dr. Jonathan Sheldon to Board of Directors, Strengthening Leadership in AI-Powered Genomic Medicine

Jonathan Sheldon, a distinguished bioinformatics and digital health executive (ex-QIAGEN, Oracle), joins SeqOne's board, bolstering their global personalized medicine expansion.

SeqOne and Agilent Announce Strategic Collaboration to Advance Liquid Biopsy Data Analysis for Oncology Applications

SeqOne and Agilent Announce Strategic Collaboration to Advance Liquid Biopsy Data Analysis for Oncology Applications

SeqOne Genomics Raises €20 Million in Oversubscribed Growth Round to Lead AI-Powered NGS Revolution in Personalized Medicine

New capital from Supernova Invest, alongside existing partners Elaia, Omnes, and Merieux Equity Partners, will accelerate SeqOne’s mission to transform genomic diagnostics worldwide, focusing on international expansion, U.S., and strategic growth.

SeqOne Launches SomaHemato: Advancing Precision in CLL Prognostics with Robust IGHV Mutational Status Analysis on the SeqOne Platform

SeqOne's SomaHemato offers robust, validated IGHV analysis for CLL prognosis, overcoming NGS short-read limits for precise clinical insights.

SeqOne Accelerates Growth and Expansion into Multi-Omics with Life & Soft Acquisition

Strategic acquisition bolsters SeqOne's multi-omics capabilities and expands service offerings with ISO-certified sequencing platform.

SimBA: A methodology and tools for evaluating the performance of RNA-Seq bioinformatic pipelines

The evolution of next-generation sequencing (NGS) technologies has led to increased focus on RNA-Seq. Many bioinformatic tools have been developed for RNA-Seq analysis, each with unique performance characteristics and configuration parameters.

DE-kupl: exhaustive capture of biological variation in RNA-seq data through k-mer decomposition

We introduce a k-mer-based computational protocol, DE-kupl, for capturing local RNA variation in a set of RNA-seq libraries, independently of a reference gen...

Clinical and Molecular Spectrum of Nonsyndromic Early-Onset Osteoarthritis

Osteoarthritis (OA) is the most common joint disease worldwide. The etiology of OA is varied, ranging from multifactorial to environmental to monogenic.

Kmerator Suite: design of specific k-mer signatures and automatic metadata discovery in large RNA-seq datasets

The huge body of publicly available RNA-sequencing (RNA-seq) libraries is a treasure of functional information allowing to quantify the expression of known or novel transcripts in tissues.